Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 13/20 | 0.44 |
| ▸ | PIK3R1 | P27986 | 2/20 | 0.35 |
| ▸ | ALOX5AP | P20292 | 3/20 | 0.35 |
| ▸ | FEN1 | P39748 | 2/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
| ▸ | MTOR | P42345 | 2/20 | 0.34 |
| ▸ | AKT1 | P31749 | 1/20 | 0.34 |
| ▸ | SYK | P43405 | 1/20 | 0.33 |
| ▸ | GRM5 | P41594 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL247498 | 0.90 | PIK3CA (0.53) | PIK3CA | |
| SCHEMBL248796 | 0.84 | PIK3CA (0.53) | PIK3CA | |
| SCHEMBL253268 | 0.82 | PIK3CA (0.48) | PIK3CA | |
| SCHEMBL245632 | 0.82 | PIK3CA (0.49) | PIK3CA | |
| SCHEMBL248614 | 0.81 | PIK3CA (0.51) | PIK3CA | |
| SCHEMBL246258 | 0.81 | PIK3CA (0.48) | PIK3CA | |
| SCHEMBL246449 | 0.80 | PIK3CA (0.49) | PIK3CA | |
| SCHEMBL246547 | 0.80 | PIK3CA (0.47) | PIK3CA | |
| SCHEMBL249015 | 0.78 | PIK3CA (0.51) | PIK3CAMTOR | |
| SCHEMBL248802 | 0.78 | PIK3CA (0.47) | PIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2588471-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF PI3K ACTIVITY | Amgen Inc. (US) | 2013-05-08 | — | — | EP | disclosed |
| WO-2012003283-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF PI3K ACTIVITY | AMGEN INC. (US) | 2012-01-05 | — | — | WO | disclosed |